UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | | November 8, 2007 |
Auriga Laboratories, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) | | 000-26013 (Commission File Number) | | 84-1334687 (I.R.S. Employer Identification No.) |
| |
10635 Santa Monica Boulevard, Suite 120 Los Angeles, California 90025 (Address of principal executive offices) (zip code) |
| | | | | |
| | | | | |
(310) 461-3600 (Registrant’s telephone number, including area code) |
| | | | | |
| | | | | |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On November 8, 2007, we issued a press release announcing our third fiscal quarter business highlights and earnings for the period ended September 30, 2007, a copy of which is furnished with this Current Report as Exhibit 99.1.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits |
| | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press release dated November 8, 2007 issued by Auriga Laboratories, Inc., announcing third quarter business highlights and earnings information. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 8, 2007 | | Auriga Laboratories, Inc. |
| | a Delaware corporation |
| |
| |
| |
By: Philip S. Pesin |
Its: Chief Executive Officer |
